ID   RIR2_HUMAN              Reviewed;         389 AA.
AC   P31350; B2R9B5; J3KP43; Q5WRU7;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Ribonucleoside-diphosphate reductase subunit M2;
DE            EC=1.17.4.1;
DE   AltName: Full=Ribonucleotide reductase small chain;
DE   AltName: Full=Ribonucleotide reductase small subunit;
GN   Name=RRM2; Synonyms=RR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=1627826; DOI=10.3109/10425179209020807;
RA   Pavloff N., Rivard D., Masson S., Shen S.-H., Mes-Masson A.-M.;
RT   "Sequence analysis of the large and small subunits of human
RT   ribonucleotide reductase.";
RL   DNA Seq. 2:227-234(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11978970;
RA   Zhou B., Yen Y.;
RT   "Characterization of the human ribonucleotide reductase M2 subunit
RT   gene; genomic structure and promoter analyses.";
RL   Cytogenet. Cell Genet. 95:52-59(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1-94 (ISOFORM 2).
RC   TISSUE=Neonatal skin;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17693683; DOI=10.1074/mcp.M700120-MCP200;
RA   Tang L.-Y., Deng N., Wang L.-S., Dai J., Wang Z.-L., Jiang X.-S.,
RA   Li S.-J., Li L., Sheng Q.-H., Wu D.-Q., Li L., Zeng R.;
RT   "Quantitative phosphoproteome profiling of Wnt3a-mediated signaling
RT   network: indicating the involvement of ribonucleoside-diphosphate
RT   reductase M2 subunit phosphorylation at residue serine 20 in canonical
RT   Wnt signal transduction.";
RL   Mol. Cell. Proteomics 6:1952-1967(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20 AND THR-33, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20 AND THR-33, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20 AND THR-33, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Provides the precursors necessary for DNA synthesis.
CC       Catalyzes the biosynthesis of deoxyribonucleotides from the
CC       corresponding ribonucleotides. Inhibits Wnt signaling.
CC   -!- CATALYTIC ACTIVITY: 2'-deoxyribonucleoside diphosphate +
CC       thioredoxin disulfide + H(2)O = ribonucleoside diphosphate +
CC       thioredoxin. {ECO:0000255|PROSITE-ProRule:PRU10014}.
CC   -!- COFACTOR:
CC       Name=Fe cation; Xref=ChEBI:CHEBI:24875; Evidence={ECO:0000250};
CC       Note=Binds 2 iron ions per subunit. {ECO:0000250};
CC   -!- PATHWAY: Genetic information processing; DNA replication.
CC   -!- SUBUNIT: Heterodimer of a large and a small subunit.
CC   -!- INTERACTION:
CC       P41002:CCNF; NbExp=12; IntAct=EBI-2339245, EBI-1207574;
CC       Q9UM11:FZR1; NbExp=2; IntAct=EBI-2339245, EBI-724997;
CC       P23921:RRM1; NbExp=3; IntAct=EBI-2339245, EBI-717006;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P31350-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P31350-2; Sequence=VSP_044917;
CC         Note=No experimental confirmation available. Ref.3 (DA477511)
CC         sequence is in conflict in position: 28:R->H. Ref.3 (DA477511)
CC         sequence is in conflict in position: 59:S->A. {ECO:0000305};
CC   -!- PTM: Phosphorylation on Ser-20 relieves the inhibitory effect on
CC       Wnt signaling.
CC   -!- MISCELLANEOUS: Two distinct regulatory sites have been defined:
CC       the specificity site, which controls substrate specificity, and
CC       the activity site which regulates overall catalytic activity. A
CC       substrate-binding catalytic site, located on M1, is formed only in
CC       the presence of the second subunit M2.
CC   -!- SIMILARITY: Belongs to the ribonucleoside diphosphate reductase
CC       small chain family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=DA477511; Type=Frameshift; Positions=87; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ribonucleotide reductase entry;
CC       URL="https://en.wikipedia.org/wiki/Ribonucleotide_reductase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X59618; CAA42181.1; -; mRNA.
DR   EMBL; S40301; AAA09577.1; -; mRNA.
DR   EMBL; AY032750; AAK51163.1; -; Genomic_DNA.
DR   EMBL; AK313719; BAG36462.1; -; mRNA.
DR   EMBL; DA477511; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC104794; AAX93099.1; -; Genomic_DNA.
DR   EMBL; AC118058; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001886; AAH01886.1; -; mRNA.
DR   EMBL; BC030154; AAH30154.1; -; mRNA.
DR   CCDS; CCDS1669.1; -. [P31350-1]
DR   CCDS; CCDS54334.1; -. [P31350-2]
DR   PIR; S25854; S25854.
DR   RefSeq; NP_001025.1; NM_001034.3. [P31350-1]
DR   RefSeq; NP_001159403.1; NM_001165931.1. [P31350-2]
DR   UniGene; Hs.226390; -.
DR   PDB; 2UW2; X-ray; 2.80 A; A=60-389.
DR   PDB; 3OLJ; X-ray; 2.10 A; A/B/C/D=66-350.
DR   PDB; 3VPM; X-ray; 2.70 A; A/B=66-350.
DR   PDB; 3VPN; X-ray; 2.25 A; A/B=66-350.
DR   PDB; 3VPO; X-ray; 2.30 A; A/B=66-350.
DR   PDBsum; 2UW2; -.
DR   PDBsum; 3OLJ; -.
DR   PDBsum; 3VPM; -.
DR   PDBsum; 3VPN; -.
DR   PDBsum; 3VPO; -.
DR   ProteinModelPortal; P31350; -.
DR   SMR; P31350; -.
DR   BioGrid; 112155; 42.
DR   DIP; DIP-24232N; -.
DR   IntAct; P31350; 22.
DR   STRING; 9606.ENSP00000353770; -.
DR   BindingDB; P31350; -.
DR   ChEMBL; CHEMBL1954; -.
DR   DrugBank; DB00242; Cladribine.
DR   DrugBank; DB05260; Gallium nitrate.
DR   DrugBank; DB05801; GTI 2040.
DR   DrugBank; DB05003; Imexon.
DR   DrugBank; DB05428; motexafin gadolinium.
DR   GuidetoPHARMACOLOGY; 2631; -.
DR   iPTMnet; P31350; -.
DR   PhosphoSitePlus; P31350; -.
DR   BioMuta; RRM2; -.
DR   DMDM; 400979; -.
DR   EPD; P31350; -.
DR   MaxQB; P31350; -.
DR   PaxDb; P31350; -.
DR   PeptideAtlas; P31350; -.
DR   PRIDE; P31350; -.
DR   DNASU; 6241; -.
DR   Ensembl; ENST00000304567; ENSP00000302955; ENSG00000171848. [P31350-1]
DR   Ensembl; ENST00000360566; ENSP00000353770; ENSG00000171848. [P31350-2]
DR   Ensembl; ENST00000615152; ENSP00000484183; ENSG00000171848. [P31350-2]
DR   GeneID; 6241; -.
DR   KEGG; hsa:6241; -.
DR   UCSC; uc021vdr.3; human. [P31350-1]
DR   CTD; 6241; -.
DR   DisGeNET; 6241; -.
DR   GeneCards; RRM2; -.
DR   HGNC; HGNC:10452; RRM2.
DR   HPA; HPA056994; -.
DR   MIM; 180390; gene.
DR   neXtProt; NX_P31350; -.
DR   OpenTargets; ENSG00000171848; -.
DR   PharmGKB; PA299; -.
DR   eggNOG; KOG1567; Eukaryota.
DR   eggNOG; COG0208; LUCA.
DR   GeneTree; ENSGT00390000013305; -.
DR   HOGENOM; HOG000255975; -.
DR   HOVERGEN; HBG001647; -.
DR   InParanoid; P31350; -.
DR   KO; K10808; -.
DR   OMA; NEVQYSE; -.
DR   OrthoDB; EOG091G0AZQ; -.
DR   PhylomeDB; P31350; -.
DR   TreeFam; TF300465; -.
DR   BioCyc; MetaCyc:HS10398-MONOMER; -.
DR   BRENDA; 1.17.4.1; 2681.
DR   Reactome; R-HSA-113510; E2F mediated regulation of DNA replication.
DR   Reactome; R-HSA-499943; Synthesis and interconversion of nucleotide di- and triphosphates.
DR   Reactome; R-HSA-69205; G1/S-Specific Transcription.
DR   SIGNOR; P31350; -.
DR   UniPathway; UPA00326; -.
DR   ChiTaRS; RRM2; human.
DR   EvolutionaryTrace; P31350; -.
DR   GeneWiki; RRM2; -.
DR   GenomeRNAi; 6241; -.
DR   PMAP-CutDB; P31350; -.
DR   PRO; PR:P31350; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000171848; -.
DR   CleanEx; HS_RRM2; -.
DR   ExpressionAtlas; P31350; baseline and differential.
DR   Genevisible; P31350; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005971; C:ribonucleoside-diphosphate reductase complex; IEA:Ensembl.
DR   GO; GO:0008199; F:ferric iron binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0004748; F:ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor; ISS:UniProtKB.
DR   GO; GO:0009263; P:deoxyribonucleotide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; IEA:UniProtKB-UniPathway.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0015949; P:nucleobase-containing small molecule interconversion; TAS:Reactome.
DR   GO; GO:0051290; P:protein heterotetramerization; IEA:Ensembl.
DR   GO; GO:0000083; P:regulation of transcription involved in G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   CDD; cd01049; RNRR2; 1.
DR   InterPro; IPR009078; Ferritin-like_SF.
DR   InterPro; IPR033909; RNR_small.
DR   InterPro; IPR030475; RNR_small_AS.
DR   InterPro; IPR000358; RNR_small_fam.
DR   PANTHER; PTHR23409; PTHR23409; 1.
DR   Pfam; PF00268; Ribonuc_red_sm; 1.
DR   SUPFAM; SSF47240; SSF47240; 1.
DR   PROSITE; PS00368; RIBORED_SMALL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   DNA replication; Iron; Metal-binding; Oxidoreductase; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN         1    389       Ribonucleoside-diphosphate reductase
FT                                subunit M2.
FT                                /FTId=PRO_0000190447.
FT   ACT_SITE    176    176       {ECO:0000255|PROSITE-ProRule:PRU10014}.
FT   METAL       138    138       Iron 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10014}.
FT   METAL       169    169       Iron 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10014}.
FT   METAL       169    169       Iron 2. {ECO:0000250}.
FT   METAL       172    172       Iron 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10014}.
FT   METAL       232    232       Iron 2. {ECO:0000250}.
FT   METAL       266    266       Iron 2. {ECO:0000250}.
FT   METAL       269    269       Iron 2. {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17693683,
FT                                ECO:0000244|PubMed:17924679,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      33     33       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1      1       M -> MGRVGGMAQPMGRAGAPKPMGRAGSARRGRFKGCWS
FT                                EGSPVHPVPAVLSWLLALLRCASTM (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044917.
FT   MUTAGEN      20     20       S->A: Enhances inhibitory effect on Wnt
FT                                signaling.
FT   MUTAGEN      20     20       S->E: Prevents inhibitory effect on Wnt
FT                                signaling.
FT   TURN         71     73       {ECO:0000244|PDB:3OLJ}.
FT   TURN         77     80       {ECO:0000244|PDB:3OLJ}.
FT   HELIX        88     99       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       104    106       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       110    112       {ECO:0000244|PDB:2UW2}.
FT   HELIX       113    118       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       121    147       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       149    152       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       156    183       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       187    194       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       196    199       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       201    203       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       204    215       {ECO:0000244|PDB:3OLJ}.
FT   STRAND      217    219       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       221    233       {ECO:0000244|PDB:3OLJ}.
FT   TURN        234    236       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       237    248       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       253    278       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       286    305       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       310    313       {ECO:0000244|PDB:3OLJ}.
FT   HELIX       317    335       {ECO:0000244|PDB:3OLJ}.
SQ   SEQUENCE   389 AA;  44878 MW;  10E6F5F84D34DA94 CRC64;
     MLSLRVPLAP ITDPQQLQLS PLKGLSLVDK ENTPPALSGT RVLASKTARR IFQEPTEPKT
     KAAAPGVEDE PLLRENPRRF VIFPIEYHDI WQMYKKAEAS FWTAEEVDLS KDIQHWESLK
     PEERYFISHV LAFFAASDGI VNENLVERFS QEVQITEARC FYGFQIAMEN IHSEMYSLLI
     DTYIKDPKER EFLFNAIETM PCVKKKADWA LRWIGDKEAT YGERVVAFAA VEGIFFSGSF
     ASIFWLKKRG LMPGLTFSNE LISRDEGLHC DFACLMFKHL VHKPSEERVR EIIINAVRIE
     QEFLTEALPV KLIGMNCTLM KQYIEFVADR LMLELGFSKV FRVENPFDFM ENISLEGKTN
     FFEKRVGEYQ RMGVMSSPTE NSFTLDADF
//
